Editorial: determining disability in IBD – ‘See(k) and you shall find’

Abstract

LINKED CONTENT This article is linked to Tannoury et al and Tannoury & Amiot papers. To view these articles, visit https://doi.org/10.1111/apt.16353 and https://doi.org/10.1111/apt.16384

Editorial commentary on Indian Journal of Gastroenterology—September–October 2021

“…Mucocutaneous (4.84%) manifestations were most common, followed by musculoskeletal (1.32%), ocular (0.88%), hepatobiliary (0.44%), and vascular (0.44) manifestations. These findings draw our attention to the myriad ramifications of IBD, which are not limited to systemic effects alone, as is emerging in other studies [ 7 ]. Clinicians should carefully assess EIMs at diagnosis and through the course of the patient’s journey to ensure optimal outcomes.…”